The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

The uninsured rate has been cut in half, but Americans are sicker, and their life expectancy is stagnating. Doing more of the ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Multi-year program advancing translational medical science research and educationCAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today celebrates ...

Weight loss drugs have risen in popularity in the recent years, but a disconnect remains between those who need the drugs and ...

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category ... Reimagining What's Possibl In a new white paper from the ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Obesity, diabetes, hypertension, and hyperlipidemia constitute risk factors for morbidity and premature mortality. Based on animal and in vitro studies, resveratrol reverts these risk factors via ...